Program
Interferon beta-1a
Also written as “Rebif®”, “RNF” and “Rebif”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.
Drug pageInterferon beta-1a: every studyMany companies study it; this page follows only the 53 they lead. All 82 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 230 open or running | phase 4since Sep 13, 2005 | Dec 15, 2004 | none ahead |
| Merck KGaA, Darmstadt, Germany | 210 open or running | phase 4since Feb 23, 2004 | Feb 23, 2004 | none ahead |
| Faron Pharmaceuticalsits history only | 30 open or running | phase 3since Nov 24, 2015 | Nov 24, 2015 | none ahead |
| Biocadits history only | 20 open or running | phase 3since May 29, 2015 | Jan 10, 2013 | none ahead |
| Cinnagenits history only | 20 open or running | phase 3since Jan 17, 2022 | Jul 14, 2018 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 13, 2009 | Nov 13, 2009 | none ahead |
| Trio Medicinesits history only | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Feb 23, 2004.
- Aug 21, 2006Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT00367484 · 460 enrolled
- Nov 27, 2006Phase 3 study in Multiple SclerosisNCT00404352 · 517 enrolled · Argentina, Australia, Austria and more
- Feb 26, 2007Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT00441103 · 180 enrolled
- Jul 30, 2008Phase 3 study in Multiple SclerosisNCT00725985 · 617 enrolled · United States, Argentina, Austria and more
- Dec 22, 2008Phase 3 study in Multiple SclerosisNCT00813709 · 402 enrolled · Argentina, Austria, Belgium and more
- Feb 24, 2010Phase 2 study in Alzheimer DiseaseNCT01075763 · 42 enrolled · Italy
- Mar 10, 2010Phase 4 study in Multiple SclerosisNCT01085318 · 38 enrolled · United States
- Jun 10, 2010Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT01142466 · 30 enrolled
- Sep 13, 2010Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT01201343 · 79 enrolled
- Jan 26, 2011Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT01285401 · 260 enrolled · Austria, Denmark, Estonia and more
- Feb 12, 2013Phase 4 study in Multiple SclerosisNCT01791244 · 93 enrolled · Germany, Sweden
- Feb 13, 2014Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT02064816 · 200 enrolled · Germany
- Apr 15, 2014Phase 4 study in Multiple SclerosisNCT02117050 · 1 enrolled · United States
- Sep 29, 2014Phase 4 study in Relapsing Multiple SclerosisNCT02254304 · 106 enrolled · Germany
TargetBeta
“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Studies
All 21 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02254304Relapsing Multiple Sclerosis · Germany | 4 | Completed | Aug 20, 2016 | 106 |
| NCT02117050Multiple Sclerosis · United States | 4 | Terminated | Apr 2015 | 1 |
| NCT02064816Multiple Sclerosis, Relapsing-Remitting · Germany | 4 | Completed | Apr 30, 2016 | 200 |
| NCT01791244Multiple Sclerosis · Germany, Sweden | 4 | Completed | Feb 29, 2016 | 93 |
| NCT01285401Multiple Sclerosis, Relapsing-Remitting · Austria, Denmark, Estonia and more | 2 | Completed | Apr 2015 | 260 |
| NCT01201343Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Jul 2010 | 79 |
| NCT01142466Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Dec 2009 | 30 |
| NCT01085318Multiple Sclerosis · United States | 4 | Completed | Feb 29, 2012 | 38 |
| NCT01075763Alzheimer Disease · Italy | 2 | Completed | May 2008 | 42 |
| NCT00813709Multiple Sclerosis · Argentina, Austria, Belgium and more | 3 | Completed | Aug 2011 | 402 |
| NCT00725985Multiple Sclerosis · United States, Argentina, Austria and more | 3 | Completed | Jul 31, 2011 | 617 |
| NCT00441103Multiple Sclerosis, Relapsing-Remitting | 3 | Completed | Nov 2008 | 180 |
| NCT00404352Multiple Sclerosis · Argentina, Australia, Austria and more | 3 | Completed | Aug 2010 | 517 |
| NCT00367484Multiple Sclerosis, Relapsing-Remitting | 4 | Completed | Jan 2006 | 460 |
| NCT00304252Crohn Disease · Germany, Italy, Sweden and more | 2 | Terminated | 192 | |
| NCT00303381Colitis, Ulcerative · Germany, Israel, Netherlands and more | 2 | Completed | Jan 2003 | 194 |
| NCT00292266Multiple Sclerosis, Relapsing-Remitting | 3 | Completed | Jun 2002 | 677 |
| NCT00287079Clinically Isolated Syndrome · Canada | 3 | Completed | Nov 2008 | 35 |
| NCT00249860Hepatitis C | 3 | Completed | Aug 2005 | 257 |
| NCT00101959Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | 0 | |
| NCT00078338Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Austria and more | 4 | Completed | Nov 28, 2006 | 764 |
How it is read
Names in the registry
- “Interferon beta-1a”, 11 entries
- “Rebif®”, 7 entries
- “RNF”, 5 entries
- “Rebif”, 4 entries
- “SNG001”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 21 studies
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- COVID-19, 3 studies
- Colitis, Ulcerative, 2 studies
- Pneumonia, Viral, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.